Biotechnology company Mesoblast (NASDAQ: MESO) shares are plummeting premarket after the company said that its COVID-19 treatment was unlikely to meet its primary endpoint.
Mesoblast shares are down 31.83% on Friday at $9.25 following Thursday’s close at $13.57. Its Australian-listed stock price fell 36.07% to A$2.41 after the news.
In a press release, the company said that the trial was aiming to achieve a primary endpoint of a 43% reduction in mortality at 30 days for treatment with remestemcel-L on top of maximal care in a trial of 300 patients with the mortality reduction target based on pilot data observed during the initial stages of the pandemic.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
However, the Data Safety Monitoring Board (DSMB) reported that while there were no safety concerns, the trial is not likely to meet its primary endpoint.
The trial has not yet accrued data on the secondary endpoints, and the company will still carry out the study using the 223 patients that are already enrolled.
